Partner David Rosen was quoted in a Washington Post article, “Regulators Take a Growing Interest in Drugmakers’ Moves to Protect Profits,” on March 19, 2015. The article discussed the competitive nature of patents for the prescription drug market, along with related antitrust issues. Rosen was quoted saying, “This industry is under a lot of scrutiny because the cost savings in the generic world are pretty high for the public.”
People
Related News
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."
June 6, 2025
In the News
Louis Lehot Comments on Crypto Company IPO – 'Definitely a home run'
Foley & Lardner LLP partner Louis Lehot commented on the initial public offering of stablecoin issuer Circle in the Law360 article, "Circle's Smash IPO Could Pave Way For More Crypto Listings."
June 5, 2025
In the News
Michael Bennett and Zack Flagel Explore Pro Tennis Antitrust Battle
Foley & Lardner LLP attorneys Michael Bennett and Zack Flagel assess the antitrust litigation embroiling professional tennis in their LawInSport article, "Break(ing) Point? The Antitrust Battle that Could Transform Professional Tennis."